CD274 and neoplasm: The difference in the proportion of patients with non-squamous mNSCLC (63.31% in the POSEIDON trial vs. 75.86% in the ARCTIC trial) and the expression of PD-L1 (only patients with a tumor proportion score of 25% or more received T+D in the ARCTIC trial, patients with tumor proportion score less than 25% also received T+D+CT in the POSEIDON trial) may be partly responsible for the difference in the median DoR between POSEIDON and ARCTIC trials (Planchard et al., 2020; Johnson et al., 2023).